Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iRadimedFRA:46K +0.61%94 5-Year Yield-on-Cost % is 0.78 as of Jul. 29, 2026, which is 3% above its 10-year median of 0.76. GuruFocus rates FRA:46K with a GF Score™ of 94/100 and a GF Value™ of €57.78 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 322 Medical Devices & Instruments companies, iRadimed ranks worse than 81.37% on this metric.
iRadimed's yield on cost for the quarter that ended in Mar. 2026 was 0.78.
The historical rank and industry rank for iRadimed's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:46K'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.33 Med: 0.76 Max: 1.24
Current: 0.78
During the past 13 years, iRadimed's highest Yield on Cost was 1.24. The lowest was 0.33. And the median was 0.76.
FRA:46K's 5-Year Yield-on-Cost % is ranked worse than 81.37% of 322
companies
in the Medical Devices & Instruments industry
Industry Median: 2.445
vs FRA:46K: 0.78
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
iRadimed 5-Year Yield-on-Cost % Related Terms
FRA:46K vs AORT, TNDM, AVNS: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, iRadimed's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iRadimed 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iRadimed's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where iRadimed's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of iRadimed is calculated as
iRadimed (FRA:46K) has a 5-Year Yield-on-Cost % of 0.78 as of Jul. 29, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on iRadimed and its competitors. This is near median its historical median of 0.76. Over the past decade, iRadimed's 5-Year Yield-on-Cost % has ranged from 0.33 to 1.24. According to the industry distribution chart, iRadimed ranks #262 out of 322 companies in the Medical Devices & Instruments industry, placing it in the top 81.4%.
Is iRadimed's 5-Year Yield-on-Cost % too high?
iRadimed's current 5-Year Yield-on-Cost % of 0.78 is near median its 10-year median of 0.76. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 1.24. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.45. iRadimed's value of 0.78 is 68.1% below this industry median. Based on the distribution chart, iRadimed ranks #262 out of 322 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, iRadimed has a GF Score™ of 94/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iRadimed's 5-Year Yield-on-Cost % compare to AORT and TNDM?
According to the Medical Devices & Instruments industry distribution chart, iRadimed ranks #262 out of 322 companies for 5-Year Yield-on-Cost %. This places iRadimed in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.45. iRadimed's value of 0.78 is 68.1% below this benchmark. Historically, iRadimed's own 5-Year Yield-on-Cost % has ranged from 0.33 to 1.24 over the past decade. While the company's 10-year median is 0.76 vs. the industry median of 2.45, iRadimed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.45, based on 322 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iRadimed's current 5-Year Yield-on-Cost % of 0.78 is 68.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on iRadimed and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iRadimed's current 5-Year Yield-on-Cost % is 0.78, which is near median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRadimed stock overvalued right now?
Based on GuruFocus' analysis, iRadimed (FRA:46K) is currently considered Significantly Overvalued. The stock's GF Value™ is €57.78, compared to a current price of €82.50 — trading 42.8% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.78, which is near median its 10-year median of 0.76 and 68.1% below the Medical Devices & Instruments industry median of 2.45. iRadimed's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For iRadimed (FRA:46K), the current 5-Year Yield-on-Cost % is 0.78 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRadimed (FRA:46K) Overvalued in 2026?
Based on GuruFocus' analysis, iRadimed stock appears to be overvalued.
The current stock price of €82.50 is trading 42.8% above its estimated GF Value™ of €57.78.
GuruFocus considers iRadimed to be Significantly Overvalued.
Key valuation signals for FRA:46K:
5-Year Yield-on-Cost %: 0.78 (near median its 10-year median of 0.76)
GF Value™: €57.78 vs. price of €82.50 (42.8% above fair value)
Industry Position: 68.1% below the Medical Devices & Instruments median (#262 of 322)
No single metric tells the full story. See the FRA:46K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
94GF Score
Get the complete analysis for FRA:46K
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:46K has been successfully added to your 
